糖尿病病中的芬瑞:减缓疾病进展的新前沿
Ibrahim S Alhomoud1, Mohamed A Albekery2, Razan Alqadi3
1Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Frontiers in medicine
|June 18, 2025
概括
糖尿病病 (DKD) 管理正在发展. 芬龙是一种新型的非类固醇矿物质皮质类受体对抗剂,为患有DKD的2型糖尿病患者提供了新的治疗选择.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DKD) 在2型糖尿病 (T2DM) 患者的发病率和死亡率显著增加.
- 目前的DKD管理侧重于氨酸-血管酶系统 (RAS) 阻断和风险因素控制.
- 像SGLT-2抑制剂和GLP-1受体激动剂这样的新兴疗法在减缓疾病进展方面表现有前途.
研究的目的:
- 审查糖尿病病管理的不断变化的景观.
- 突出提升芬瑞作为DKD的新型治疗剂.
- 讨论finerenone独特的药理和结构性质以及临床影响.
主要方法:
- 对当前和新兴的DKD治疗方法的文献综述.
- 分析费内伦的药理动力学和药理动力学概况.
- 与现有的类固醇矿物质皮质体受体对抗剂 (MRAs) 进行费内伦的比较.
主要成果:
- 与类固醇MRA (spironolactone,eplerenone) 相比,费内伦具有不同的特性.
- 它的新机制为DKD管理提供了新的途径.
- 临床数据支持其在减缓病进展方面的作用.
结论:
- 菲内伦代表了DKD治疗的重大进步.
- 它的独特特征值得在治疗DKD的T2DM患者时加以考虑.
- 进一步的研究将阐明其对脏结果的长期影响.
相关概念视频
Renal Failure: Dose Adjustments
167
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
167
Heart Failure Drugs: Diuretics
505
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
505
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
Chronic Kidney Disease III: Interprofessional Care
87
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
87
Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
Acute Kidney Injury IV: Diagnostic Studies and Prevention
64
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
64


